John Lunger

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Abingdon, Oxfordshire, United Kingdom
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ John Lunger
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for John Lunger

Form 4 holding Chief Patient Supply Officer

Adaptimmune Therapeutics PLC

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
7,510
Estimated value
$4,362
Report date
17 Jan 2025
Price
$0.5808
Ownership
Direct
Form 4 holding Chief Patient Supply Officer

Adaptimmune Therapeutics PLC

Security class
Option to purchase Ordinary Shares
Shares / value
1,074,696
Estimated value
Report date
20 Feb 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

GENOCEA BIOSCIENCES, INC.

Security class
Stock Option (Right to Buy)
Shares / value
30,000
Estimated value
Report date
03 Mar 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by John Lunger

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .